NEW YORK, December 29, 2025, 10:30 PM ET — Market closed
- Stryker shares closed down 0.5% at $352.50 as U.S. stocks pulled back.
- Investors are watching a Dec. 31 shareholder record date for the next dividend and a Jan. 1 leadership change.
- Fed minutes and weekly jobless claims are next on the macro calendar in a thin holiday week.
Shares of Stryker Corp (SYK) ended Monday down 0.5% at $352.50, giving back ground as Wall Street slipped in the final week of 2025.
The late-day drift mattered more than usual for a stock that has a near-term calendar: a shareholder record date for the next dividend lands this week, and Stryker’s new president and chief operating officer is set to take the role on Jan. 1.
With trading volumes typically lighter around year-end, modest risk-off moves can show up quickly in large-cap healthcare names, especially after a tech-heavy rally pushed major indexes to record highs last week.
Stryker traded between $351.33 and $355.88 in the regular session, after opening at $355.07, with about 1.3 million shares changing hands.
The broader market closed lower as heavyweight technology stocks retreated; the S&P 500 fell 0.35% and the Nasdaq lost 0.5%, Reuters reported. Investors are looking ahead to Federal Reserve meeting minutes and weekly jobless claims in an otherwise data-light week, with U.S. exchanges also set to close for New Year’s Day.
Peers moved in the same direction. Medtronic slipped about 0.4%, while Zimmer Biomet and Boston Scientific each eased roughly 0.2%–0.3%.
Income-focused investors have also been tracking Stryker’s next payout. The company said earlier this month it declared a quarterly dividend of $0.88 per share, payable Jan. 30 to shareholders of record at the close of business on Dec. 31, an increase of 4.8% versus the prior year and previous quarter.
Management changes are also approaching. Stryker said Spencer Stiles will become president and COO on Jan. 1, and CEO Kevin Lobo said the move “strengthens our ability to sustain high growth.” Stryker
Stryker is a medical-technology company with businesses spanning MedSurg, Neurotechnology and Orthopaedics, and it says its products and services impact more than 150 million patients annually.
From a price-action standpoint, Monday’s low near $351 left the stock just above the $350 area that traders often treat as a near-term support level. The day’s high near $356 marked the next resistance band if buyers return.
Before the next session, the dividend record date and the Jan. 1 leadership handoff are likely to keep Stryker on traders’ radar even if broader volumes stay muted into year-end.
Looking further out, Nasdaq’s earnings calendar lists Jan. 27 as an estimated date for Stryker’s next quarterly report, when investors will look for fresh detail on procedure demand, pricing and margins heading into 2026.
